PI3K activity is the main predictor of mitogen-activated protein kinase kinase (MEK)-inhibitor resistance in KRAS-driven CRC [33,34] and thus, the additional use of a PI3K inhibitor could overcome resistance to MEK inhibition [35]. This evidence concerns the gene WNK2 and colorectal carcinoma.